To compare the progesterone forms used for luteal phase support during gonadotropin-induced ovulation induction in terms of pregnancy success.
Materials and Methods: This study included 315 cases of controlled ovulation stimulation and IUI, using from gonadotropin therapy applied to Zekai Tahir Burak SUAM infertility polyclinic between March 2017 and February 2018. Demographic, clinical variables and pregnancy rates were recorded from hospital records and patient files. When at least 1 dominant follicle with ≥18 mm diameter was obtained on ultrasonography, ovulation was performed with 250 μg recombinant hCG or 10000 IU urinary hCG and IUI treatment was performed after 36 hours. Patients were divided into two groups; given 8% vaginal gel or natural oral micronized progesterone capsule as luteal phase support. The groups were statistically compared in terms of the variables mentioned.
Results: The mean age of the patients included in the study was 28.7±5.0 and 28.8±5.4 in both groups, respectively (p=0.839). There was no statistically significant difference between groups in terms of age, BMI, hormonal parameters, duration of infertility, endometrium thickness on HCG day (p>0.05). When the clinical pregnancy rates are examined; 14.2% (n=22) in the group with natural micronized progesterone and 12.5% (n=19) in the group using vaginal progesterone (p=0.7).
Conclusion: Oral progesterone form may be preferred in patients with appropriate indication instead of vaginal progesterone form because of its easy applicability and lower cost of treatment.